人附睾蛋白4临床应用研究进展  

Advances of Human Epididymis Protein 4 in Clinical Application

作　　者：王雅菲[1] 托娅[1] 王丽娟[1] 

机构地区：[1]内蒙古医科大学附属医院检验科,内蒙古呼和浩特

出　　处：《亚洲肿瘤科病例研究》2016年第3期39-44,共6页Asian Case Reports in Oncology

基　　金：内蒙古自治区自然科学基金(2014MS0854)。

摘　　要：人附睾蛋白4 (human epididymis 4, HE4)是近年来新发现的肿瘤标志物,血清HE4水平作为卵巢癌诊断、疗效评估及预后判断的新指标已经逐渐应用于临床。现有研究显示HE4在肺癌患者血清和恶性胸腔积液患者胸水中呈现较高水平表达,提示其在肺癌诊断、预后评估方面的良好作用。本文就HE4在卵巢癌及肺癌的临床应用作一综述。Human epididymis protein 4 (HE4) as a novel tumor marker is found in recent years. Serum HE4 level as a new indicator for the diagnosis, therapeutic evaluation and prognosis of ovarian cancer has been applied to the clinical gradually. The existing research shows serum HE4 of patients with lung cancer and HE4 in pleural effusion of patients with malignant pleural effusion presented higher levels of expression, suggesting a good role in the diagnosis and the prognosis evaluation of lung cancer. This article reviews the research of HE4 in clinical application of ovarian cancer and lung cancer.

关 键 词：HE4 卵巢癌 肺癌 恶性胸腔积液 

分 类 号：R73[医药卫生—肿瘤]